Medigene AG
MediGene AG english
MediGene’s Revenues Rise from Amendment of Schering Collaboration Agreement
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
MediGene’s Revenues Rise from Amendment of Schering Collaboration Agreement
Martinsried / San Diego, November 2, 2001. MediGene AG (Neuer Markt MDG), the
German-American biopharmaceutical company, has concluded an amendment of the
license and collaboration agreement with its strategic partner Schering AG (FSE:
SCH; NYSE: SHR) for the joint development of a vaccine for the treatment of
pre-cancerous cervical lesions. The amendment removes MediGene’s contingent
reimbursement obligations to Schering AG under the contract and adjusts future
milestones and royalties payable by Schering AG to MediGene. As a result,
MediGene will now book an additional 2.3 million EURO as revenues (i.e. “other
operating income”) for the current fiscal year. That amount had been booked as
deferred income prior to the contract amendment.
This ad hoc release contains forward-looking statements that involve risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of MediGene as of the date of this release. These forward looking
statements are no guarantees for future performance, and the forward-looking
events discussed in this press release may not occur. MediGene disclaims any
intent or obligation to update any of these forward-looking statements.
end
For further information please contact:
MediGene AG
email: investor@medigene.de
fax: ++49 – 89 – 85 65 29-20
Christine Bohner, Manager Public Relations, phone: ++49 – 89 – 89 65 29-16
Michael Nettersheim, Manager Investor Relations, phone: ++49 – 89 – 85 65 29-46
end of ad-hoc-announcement (c)DGAP 02.11.2001
——————————————————————————–
WKN: 502090; Index: NEMAX- 50
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
022121 Nov 01
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found